Eton Pharmaceuticals (NASDAQ:ETON) held its first-quarter earnings conference call on Thursday. Below is the complete transcript from the call.

Benzinga APIs provide real-time access to earnings call transcripts and financial data. Visit https://www.benzinga.com/apis/ to learn more.

View the webcast at https://edge.media-server.com/mmc/p/w3ob9qff/

Summary

Eton Pharmaceuticals reported a 73% year-over-year increase in product revenue, achieving $24 million in sales for the first quarter of 2026.

The company launched two new products, Desmoda and Hemangiol, and raised its full-year revenue guidance to exceed $120 million, up from $110 million.

Adjusted EBITDA for the quarter was $5.7 million, and the company aims for a 30% adjusted EBITDA margin for the full year, with a long-term goal of 50% by 2028.

Eton Pharmaceuticals' portfolio diversification drove growth, with significant contributions from products like Increlux and Alkindi.

The company is advancing multiple R&D projects, including the Increlex label harmonization study and ET700 development, with potential market expansions.

Management highlighted operational efficiencies, such as maintaining low G&A expense growth and leveraging a specialty pharmacy for drug distribution.

The company remains focused on acquisitions to expand its rare disease portfolio, aiming for $200 million annual revenue by 2027 and $500 million by 2030.

Full Transcript

OPERATOR

Good afternoon and welcome to the Eton Pharmaceuticals First Quarter 2026 Financial Results Conference call. At this time, all participants are in listen only mode. Following the formal remarks, we will open the call up for your questions. Please be advised that this call is being recorded at the company's request. At this time I'd like to turn it over to David Krempa, Chief Business Officer at Eaton Pharmaceuticals. Please proceed.

David Krempa (Chief Business Officer)

Thank you operator Good afternoon everyone and welcome to Eton's first quarter 2026 conference call. This afternoon we issued a press release that outlines the topics we plan to discuss on today's call. The release is available on our website, etonpharma.com joining me on our call today we have Sean Brynjelsen, our CEO, James Gruber, our CFO, Judy Matthews, our Executive Vice President of Finance and Ipik Trinkhaus, our Chief Commercial Officer. In addition to taking live questions on today's call, we will also be answering questions that are emailed to us. Investors can send their questions to [email protected] before we begin, I would like to remind everyone that remarks made during the call may contain forward looking statements that involve risks and uncertainties that could cause actual results to differ materially from those contained in these forward looking statements. Please see the forward looking statements disclaimer in our earnings release and the risk factors in the company's filings with the sec. Now I will turn the call over to our CEO Sean Brynjelsen. Thank you David Good afternoon everyone and thank you for joining us today. The first quarter was another great quarter for Eaton. We achieved record product sales delivering 73% year over year product revenue growth. We launched two new major products, Desmoda and Hemangiol and we made great strides advancing our R&D programs with the achievement of several development milestones. We will discuss all of these items and more on the call today on the quarterly results. It was another great quarter for Eaton with 24 million in product sales, an increase of 73% year over year. Our growth continues to be driven by contributions across the product portfolio including Increlux, Alkindi, Galzan and Curglimic Acid, highlighting the diversification and durability of our rare disease portfolio. This impressive revenue growth did not even include the benefit of the product launches of Desmoda and Hemangiol since they launched in mid March and May respectively. Based on the outperformance in the first quarter and the trends we are seeing midway through the second quarter, I'm pleased to report that we are raising our full year revenue guidance. We now expect revenue to exceed 120 million, up from our previous guidance of 110 million. Importantly, we delivered this notable first quarter revenue growth in a highly profitable manner. We grew product revenue by 73%, but G&A spending increased by only 14% year over year on a GAAP basis and 22% on a non GAAP basis. The majority of the G and A increase was due to increased costs of FDA annual program fees. Now that we no longer qualify for the Orphan PDUFA exemption rather than the true increases in our discretionary spend, adjusted EBITDA for the quarter was $5.7 million, or 24% of revenue. We continue to expect to achieve a greater than 30% adjusted EBITDA margin for the full year and believe we are on track to reach our goal of a 50% adjusted EBITDA margin by 2028. The results are a testament to the effectiveness and scalability of our unique rare disease model and infrastructure. Our nimble, proven infrastructure has allowed us to launch two new products in 2026 so far without a significant increase in expenses and without impacting the execution of growth in our existing portfolio. We expect to see similar trends in the coming quarters as we continue to quickly grow revenue and bring to market new rare disease therapies. Turning to product specifics, I will start with our exciting new launch of Hemangiol which took place just a matter of days ago. Hemangiol is the only FDA approved treatment for infantile hemangiomas which are non cancerous vascular tumors that appear shortly after birth and can sometimes lead to serious complications including loss of vision, trouble breathing or permanent disfigurement. Hemangiol treatment is typically initiated as soon as an infant is diagnosed, which is usually before 6 months of age and patients normally stay on treatment for approximately six months. Hemangiol is a remarkable product with impressive efficacy and clinically proven safety. The results are often life changing for patients and their families. If you have not done so, I encourage you to search for before and after photos of severe infantile hemangiomas treated with hemangiol to gain some perspective on how dramatic the results can be. With Hemangiol we saw an opportunity to add meaningful value to an important treatment by, among other things, streamlining therapy access and distribution and improving patient support. Hemangiol is a time sensitive treatment and we're dedicated to helping patients start therapy quickly and supporting families from the moment of prescription. Through treatment, Hemangiol expanded Eaton into a third therapeutic area, pediatric Dermatology, and importantly brought an incredibly experienced team into the organization that was already promoting Hemangio. This team has spent nearly a decade supporting physicians, families and patients within this community and and have built deep long standing relationships focused on helping children access hemangiol. One of the things we were most excited about in this acquisition was the opportunity to combine that experience and commitment to patients with Eton's rare disease commercialization model and patient support infrastructure. We believe Eton's focused rare disease approach, including Eaton Cares, high Touch patient support, specialty pharma infrastructure and our no Patient Left behind philosophy will further strengthen the work this team has already been doing for years on behalf of patients and families. We have already implemented several changes that we believe will improve the therapy experience for patients and providers and add value, including we have streamlined the distribution, shifting to a rare disease focused model that reduces fragmentation and improves visibility and efficiency during the patient journey. Under the prior structure, prescriptions could move across multiple pharmacies and intermediaries, which often created confusion for providers and families around where prescriptions were located, who was responsible for fulfillment and how to resolve access issues quickly. Secondly, we have launched our full Eaton Cares patient support program including streamlined $0 copay support for commercially insured patients and expanded patient assistance programs for uninsured and underinsured families. Previously, many families were paying approximately $55 per bottle and in some cases more than $100 per month depending on dosing and coverage, while access to copay support and financial assistance was often fragmented and difficult for offices and families to navigate. Third, we are already building upon the strong physician relationships the team developed over many years and are taking the next step in expanding engagement with thought leaders, professional societies and broader healthcare provider education initiatives to further increase awareness, education and appropriate patient identification within the treatment window. And lastly, we are actively engaging with the patient advocacy community around Hemangio and are increasing our investment in long term commitment to advocacy, partnerships, caregiver education and community support initiatives. Our goal is not simply to support the therapy itself, but to become a more active and visible partner to the broader patient community through meaningful engagement, education and resources. The responses from advocacy organizations and professional society partners have been incredibly positive, them welcoming Eton's commitment to expanding patient support, access, resources and long term investment in the community. Historically, we believe there has been significant usage of off label adult propranolol formulations that are approved for cardiovascular indications. These adult formulations contain alcohol, sugar and other preservatives that are not suitable for infants. By contrast, Hemangiol, which is the only FDA approved treatment for infantile hemangiomas, was formulated specifically for infants without containing alcohol or sugar. During our due diligence, we found that the primary reasons for using off label adult product were one the fact that the adult product had a lower copay than the $55 Hemangiol copay and 2 a lack of awareness among parents and prescribers about the alcohol and other excipients that are present in the adult formulation. We have addressed the copay issue with our $0 copay program and we plan to address the awareness issue through our investments and efforts in new campaigns targeted at both prescribers and caregivers. There are still many variables and uncertainties involved with the launch. However, our preliminary view is that between our free drug patient assistance program, government patients and certain commercial payer contracts we inherited, we estimate that around 60 to 65% of the volume may be near zero revenue, which should result in an estimated average net price per patient of around $8,000 to $10,000 per full course of therapy. Of course, this is a preliminary estimate and number of factors such as patient mix could cause the actual number to differ materially. We should have more precise insight by our next earnings call in August and we'll update you accordingly. While it is a massive undertaking to get thousands of patients transferred from a broad distribution to a new single pharmacy in such a short period, our team has been preparing and working hard to complete it quickly and ensure that the process is as smooth as possible for families and prescribers. We're still early in Hemangio's launch relaunch, I should say, but we have experienced cooperation from certain priorities dispensing pharmacies which we believe will help the situation and the transition. Hemangio's revenue contribution to second quarter results is expected to be limited since it is launching mid quarter and it may take several weeks or months to get patients fully transferred to the new pharmacy. We expect to start seeing a sizable revenue contribution beginning in the third quarter and while it is still too early in the launch to say definitively, since there are a number of variables yet to play out, we believe that Hemangiol could be our largest product in 2027. Eton also launched Desmoda during the first quarter shortly after its FDA approval. As the first and only FDA approved desmopressin oral solution, Desmoda is a game changer for patients because it eliminates the need to split or crush tablets, allowing for very precise dosing. Thought leaders in the community have described Desmoda as potentially transformative given how individualized desmopressin dosing is from patient to patient and even within the same patient over time throughout their treatment journey. Historically, patients and providers have often had to rely on suboptimal workarounds using tablets, nasal sprays, injections, none of which are designed to provide the combination of oral administration and precise flexible dose titration that many patients require. During our March earnings call, we were just a few weeks into the Desmoda launch, but I share that I was encouraged by what I saw. I am pleased to say the excitement level has continued in April and thus far in May. I am proud of our operations and commercial team's exceptional launch plan and execution and I believe that it was the best executed product launch at Eton's history and sets a new standard for future product launches. Since day one of the launch, peer to peer education efforts have complemented targeted field engagement across key accounts, supporting early awareness and clinical dialogue. In parallel, Eaton has had strong opportunities to engage with thought leaders at national and regional conferences. Earlier this month, our team attended two of the most important endocrinology conferences of the year, the Pediatric Endocrinology Nursing Society and Pediatric Endocrine Society Annual meetings. The timing was very favorable coming in the midst of our Dysmoda launch and our team was able to take advantage of the opportunity to to engage with hundreds of leading pediatric endocrinology prescribers about Desmoda. Importantly, the feedback was overwhelmingly positive. We believe the launch has also opened doors to important institutions that historically could be difficult to access, creating broader opportunities for meaningful dialogue not only around Dysmoda but across the rest of our pediatric endocrinology portfolio, including Alkindi, Increlux and Kindivi. We believe the impact of these engagements will continue to build in the coming weeks and months. Desmoda fulfills a very specific need and we've seen an enthusiastic reception from prescribers. Desmoda is being promoted by the same team of pediatric endocrinology rare disease specialists who promote Alkindi, Kindivi and Increlux. So far, the product launch is meeting my high expectations and we continue to believe it could reach peak sales of 30 to 50 million. Turning to the rest of our commercial products, the story remains consistent with that of the last few quarters. We continue to see strong, steady growth from across our diversified portfolio. Increlix, Elkindi, Sprinkle and Galzan all provided major growth contributions in the quarter. As we have discussed before, we believe we have captured relatively small share of the market opportunity for all three of these key growth products, so we continue to believe that they have long runways for growth ahead of them on the R&D side of Eaton. We have made strong progress advancing our pipeline and achieved a number of critical milestones in recent months. First, on Increlex, the label harmonization program. I am pleased to share that we now have received the FDA's clearance to proceed with our proposed clinical study. We intend to initiate the study in the second half of this year. The study will track approximately 30 patients over five years or until they reach full adult height with a primary endpoint of change in average annual height velocity at month 12 compared to pretreatment height velocity. As we've discussed extensively, we see a significant opportunity to expand the potential patient population by harmonizing the US definition of severe primary IGF1 deficiency to match that of Europe. If we are successful with harmonizing the label, the we believe the Increlix market opportunity could increase fivefold in the United States on ET 700, our extended release zinc acetate. We announced that a pilot study has been initiated to test the efficacy of ET700 relative to Galzin and placebo in a double blinded placebo controlled clinical trial comprised of 36 healthy volunteers. PET scans with radioactive tracer copper will compare the effects on intestinal copper absorption of Galsem taken three times daily, ET 700 taken twice daily plus a placebo taken daily as well and a placebo also, I'm sorry, taken three times daily. The study treatment will last four weeks and we expect to have the top line results in the second half of 2026. If early results are positive, they could lead to a pivotal clinical study in early 2027. We believe ET700 could exceed 100 million of annual peak sales in the United States once it's approved on our Kindivi label expansion program where we are seeking to expand the FDA approved range of the label beyond the current label of ages 5 and up. We are wrapping up final patient dosing in our bioequivalency study and expect to have results in the next couple of months. If successful, that will allow us to file our supplemental filing to the existing NDA in the third quarter and potentially receive approval in the second quarter of 2027. We have continued to see tepid uptake of Kindivi with its current restrictive label and believe the extended label will be the catalyst to see greater adoption. In addition, we progressed Emglidia, our oral liquid glyvuride program for the treatment of neonatal diabetes. Emglidia is approved and widely used in Europe but has not been approved in the United States. Currently there are no FDA approved treatments for neonatal diabetes, so it represents a critical unmet need. AM Glydia is a perfect strategic fit for us. It treats an extremely rare condition impacting only a few hundred patients in the United States and it is prescribed by pediatric endocrinologists, two characteristics that we specialize in here at Eaton. We recently filed an IND with the FDA which should allow us to initiate the required bioavailability study by July of this year. Based on our current timelines, we expect to submit the product's NDA in the fourth quarter, which would give us the potential to deliver a high value product launch in 2027. As you've heard this afternoon, it's been a great start to the year and we're well positioned for an exceptional 2026. The momentum from our existing products remains strong. We've added two additional high value product launches. We're meaningfully adding and advancing enhancing our pipeline to fuel long term growth and as always, we're continuing to pursue acquisition opportunities to expand our portfolio and add incremental revenue while maintaining our disciplined approach to operating expenses. Based on the strong performance in Q1, I believe we remain on track to reach the following four long term goals I outlined in March. Number one, build the largest rare disease portfolio in the United States, 2 reach a 200 million annual revenue run rate by end of 2027, 3 achieve a 50% adjusted EBITDA margin profile in 2028 and 4th reach $500 million of annual revenue in 2030. Thank you for your ongoing support and we look forward to keeping you apprised of the many exciting milestones ahead. Before I turn it over to James for the final time, I'd like to take a moment to personally thank him for his contributions and and dedication to the organization over the last four years. He's done an exceptional job leading our finance department during a period of rapid growth as we grew from two to 10 commercial products in short order. Thank you James for all you've done on behalf of Eaton. On June 1st, Judy Matthews will take over as CFO. Judy joined us last month as Executive Vice President of Accounting and Finance and has been quickly getting caught up to speed on our business. Judy previously led finance departments of high growth pharmaceutical companies and we're excited to have her on board with that. I'll turn it over to James to discuss the financial results. James thank you Sean.

James Gruber (Chief Financial Officer)

First quarter revenue increased 40% to $24.3 million compared to $17.3 million in the first quarter of 2025 and we had $3.3 million of licensing revenue in the first quarter of 2020. Product sales and royalty revenue were 24.3 million during the quarter compared to 14.0 million in the prior year period, an increase of 73% driven by strong growth across the portfolio, in particular Incralex, Alkendi, Sprinkle Galzan and Curglimic Acid as well as from the addition of sales from Kindivi which was approved and launched in mid-2025. Gross profit for the quarter was $14.7 million compared with $9.9 million in the prior year period, an increase of 49% primarily due to increased product sales. Adjusted gross profit which adjusts for the impact of acquired inventory, step up adjustments and Intangible amortization was 16.2 million in the fourth quarter of 2026 or 67% of revenue compared to adjusted gross profit of 12.0 million and 69% of revenue in the prior year period. First quarter of 2026 included revenue from Increlex sales outside the US which was dilutive to gross margin. We continue to expect to Deliver Full Year 2026 Adjusted Gross Margin of at least 70% and reach between 75 and 80% in the coming years. Hemangiol and Dysmoda are both expected to have gross margin profiles well above our historic company average. R and D expenses for the quarter were 1.9 million, an increase of 0.7 million compared to 1.2 million in the prior year period primarily due to higher clinical study expenses associated with the Condivi label expansion and ET700 development activity. We continue to expect full year 2026 R&D spending to be above last year's 7.8 million but less than 10 million. General and administrative expenses for the quarter were 10.4 million compared with 9.2 million in the prior year period on an adjusted basis which removes the impact of share based compensation, transaction related costs and other one time expenses. GNA expense was 9.0 million compared to 7.3 million in the prior year period. Largest driver of the increase was higher FDA annual program fees since Eaton no longer qualifies for the orphan Prescription Drug User Fee Act (PDUFA) exemption as we now exceed the revenue threshold required to qualify. These fees were responsible for 0.9 million of the year over year G and A increase. The remaining increase was largely due to incremental headcount to support the growing portfolio. Adjusted EBITDA for the first quarter of 2026 was $5.7 million or 24% of revenue compared to $3.7 million or 21% of revenue in the first quarter of 2025, which had the benefit of licensing revenue. Our adjusted EBITDA will likely see fluctuations quarter to quarter depending on the timing of RD expenses and Ex US Increlex orders, but we expect the full year adjusted EBITDA margin to be above 30%. Total company net income was 1.6 million for the quarter, compared to a net loss of 1.6 million in the prior year period. Net income for basic and diluted share during the quarter was $0.06 and $0.05 respectively, compared to a net loss per basic and diluted share of $0.06 in the prior year period. On a non GAAP basis, we reported net income of 4.5 million for the first quarter of 2026 compared to 2.4 million in the prior year period, and diluted earnings per share of $0.14 for the first quarter of 2026 compared to $0.07 per share in the prior year period. In the first quarter we generated $7.4 million in cash flow from operations, paid $14 million for hemangiol, and finished the quarter with $19.7 million of cash on hand. We recently amended our existing $30 million credit facility, which lowered our interest rate by approximately 200 basis points at no cost to Eaton and no change to the end of 2027 maturity date. We remain in a very strong financial position and expect to see our cash balance grow significantly throughout the year. Even with planned debt principal repayments, we expect to have significant excess cash at our disposal that can be used for accretive product acquisitions. In addition, given our significant EBITDA generation and our diversified portfolio, we believe we would have significant debt capacity available to us should a larger acquisition opportunity present itself. Before we conclude, I'd like to express my sincere gratitude to Sean and the entire team here at Eaton for the opportunity to work alongside such a talented, dedicated and passionate group of professionals. It's been a privilege to make a small contribution to Eaton's remarkable growth and success, and most importantly to the company's mission of improving the lives of the rare disease patients we serve. I'm extremely appreciative of the relationships and accomplishments that we've shared, and I remain confident that Eaton will experience continued success and make a lasting impact on the health care community for many years to come. This concludes our remarks on first quarter results and with that we'll turn it back over to the operator for Q and A.

OPERATOR

Thank you. At this time we'll conduct a question and answer session. As a reminder to ask a question, you'll need to press Star 11 on your telephone and wait for your name to be announced. To withdraw your question, please press star 11 again. Please stand by when we compile the Q and A roster. And our first question comes from the line of Madison Osadi of BYU Securities. Your line is now open.

Madison Osadi

All right, thanks for taking my question and congrats on the quarter. And James, congrats on all the success here at Eaton and wishing you the best of luck. Thanks, Madison. Yeah, absolutely. So when we look at the product level dollar contribution behind your $10 million guide, maybe just walk us through it. And we should probably assume this is 4Q loaded. And then secondly, regarding the Hemangiol price, maybe walk us through the 8k per patient per year. How does this compare to the base price that Eton had it set at? And I'm guessing this captures a typical six month course. And then if you could, any clarity into the proportion of the 8,000 branded patients that are retaining coverage at this new list price. And maybe since it's still pretty early, you could just talk about kind of your expectations for that going forward. Thanks.

James Gruber (Chief Financial Officer)

Sure. Madison, starting with your question on the guidance, increase in guidance. The Hemangio launch was a big part of that as we got more comfortable launching it and a little more insight into what we thought it could do this year as well as outperformance from the rest of our portfolio. You know, we had a strong Q1, we were happy with the results. We're seeing good Trends already in Q2. We're happy with the Desmopressin launch. So a combination of everything but Hemangiol was definitely one of the important drivers of that. In terms of your question on the net price, yes, we do expect to net more than it was previously netting. We walked through roughly 60 to 65% of the patients will likely be non revenue generating or very low revenue generating, but it should average out to the around that 8 to $10,000 net price per patient. That's our current estimate. Obviously, as you alluded to, it's still very early. We're only two weeks into it. I think it's too early to make any definitive statements. To answer your question about the coverage, we historically have very good coverage on our products, so we expect that to continue, but too early in the launch to make any statements about that. Understood. Thank you all. Thank you.

OPERATOR

One moment for our next question. And our next question comes from the line of Charles Wallace of AT Wainwright is now open.

Charles Wallace

Hi, thanks for taking my question. This is Charles on for RK from Acu. So for my first question, something kind of struck me on the call, you said that Hemangiol could be the largest product by 2027. And I was just kind of curious. Currently, like, on an annual run rate, like, what is currently the largest product currently sitting at. For my first question. Thank you. Hi, Charles, this is Sean.

Sean Brynjelsen (Chief Executive Officer)

We. I've indicated Increlites is our current largest product that continues to grow as well. You know, with Hemangiol, we have obviously big expectations for it. We've transferred a large number of the patients over to. And we're continuing that transfer process. We'll provide a little bit more color, I would imagine, on future calls, but we do want to see how this ramps before we can, you know, maybe give some directional guidance on. On that. Historically, we have not broken out sales by product, but we've spoken descriptively of it, and I think we'll certainly do that and revise our guidance as it transpires. Great. And I guess for my second question, so I guess where are you currently with the patient number for Increlex and are you confident with the 120 patients at the end of the year? Yeah. So again, we're not going to get into patient counts. Otherwise I'll be giving patient count updates on every call. I can tell you that we're very much on track with what we've stated previously. We're very pleased with incorrect performance. We have patients. It's been a great product and it's a reason why it's our largest. We are also looking at initiating that label expansion study. So we do have significant plans for the product and we'll keep everyone apprised as that enrollment occurs and as we get closer to being able to file that label update. And sorry, one more question, if I may. So I was just curious if, you know, as you're acquiring all these products, is it one specialty pharmacy that's handling all the. All these drugs in the distribution? That is correct. As we. That's a good question, actually, because we've been, you know, we certainly. That's where we're at today. And as long as they can continue to service our needs and meet our objectives for our portfolio, and we're very happy with them. But we are. We do have aspirations to have the largest rare disease portfolio in industry. And if ever comes a point where we think we need to add another specialty pharmacy, we'll do that. But for right now, we're very pleased with Inovo and the work that they do. Great. Thank you so much for taking the questions. Pleasure.

OPERATOR

Thank you. One moment for our next question. Our next question. Comes to the line of Chase Knickerbocker of Greg Highland is now open.

Chase Knickerbocker

Good afternoon. Thanks for taking the question. And congrats on another nice quarter here. Sean, could you maybe just bridge the kind of change in guidance? Was the updated raised guidance? Was it solely driven by kind of refining the Hemangiol model or what else drove it as far as how your assumptions changed from March to now?

Sean Brynjelsen (Chief Executive Officer)

Thanks. Sure. So, as David had indicated earlier, we have driven. We've raised that guidance for a number of factors. Certainly Hemangiol was a key part of that to our base business. The commercial sales levels continue to be very strong. And as we're going into, you know, the past few weeks, we see that momentum continue, you know, really across the board. We've been kind of hitting our numbers that we expect. And I guess the. The third thing is Desmoda, that launch is bringing in a significant number of patients. We're very happy with the launch. We just got out of a endocrinology meeting where there's a tremendous amount of excitement on that product. And I'm hoping to provide a little bit more clarity on what we think that ultimately that product can do. We've given off that guidance of 30 to 50 million. We'll update that, I imagine, on future calls, and we'll see how. But all of that kind of came together and we said more than 120. So obviously it's more than 120. We don't. We'll leave it at that and we'll see what happens. Helpful.

Chase Knickerbocker

And maybe if I can draw some cross currents between your experiences with Gelzen and Hemangiol here. I mean, you guys did a pretty good job of switching those patients pretty quickly into your distribution platform. I mean, maybe talk about some of the learnings that you had from Galzen and the potential for any sort of opportunity to do a little bit better than you guys are expecting as far as the kind of switching of those patients into your platform. Because again, we did outperform on Galsen. So maybe just kind of talk about if that's a fair comparison and just some of your learnings.

Ipik Trinkhaus (Chief Commercial Officer)

Sure, Chase. I'm going to turn that question over to our chief commercial officer. Hi, Chase. Thank you for the question. That is actually a great parallel. Few things that are very similar and few things that are different. I think with Galzan, it was all open network. It was multiple pharmacies. We actually didn't even have the luxury at the time of collaborating with those pharmacies. So we kind of had to find all those patients and I think we did a very good job, very effective job. And we knew at the time, without any numbers, anything that we inherited from the previous ownership that there was around 200 to 300 patients that were already on Galzan. And I think we already shared before. We are already over those numbers. We are about 300 patients already within the course of a year which obviously was a very effective transition without having any collaboration. I think with Hemangiol the positives there obviously are there were 17 pharmacies but this is also 8,000 patients. It's a big, much bigger existing base of active patients and basically pulling them from some local small pharmacies, some big pharmacies like Walgreens. So we've been working very hard for the past 60 days between our sales team putting transition agreements with some of those pharmacies as well as no our specialty pharmacy, pulling those transfers through which has been very good 60, almost 60% of that 8,000 base. We were able to actually put some sort of a collaboration with the former pharmacies to agree to transfer the patients so that we've been very good. But at the same time it's a much bigger volume of patients to serve and make sure that there's continuity of care. Nobody's behind without their drug. It's a much shorter course of therapy. That's another important distinction with Galatin. Obviously it's a lifetime chronic therapy. So we still are finding those patients who were on Galzin but also converting from, from patients who were never Benam Gals and on the competitive over the counter non Rx therapy. So that's the goal right now that conversion. But with Hemangiol it's the time is of essence because we need to get those 8,000 patients into our system, serve them without any disruption. But also it's a six month therapy window so we need to start acquiring new patients as well. Helpful color.

Chase Knickerbocker

Thank you. And then maybe just last for me, James, one last question for you here. Just as we think about the magnitude of the amount of OUS revenue for Increlux in the quarter, if you could share that and then just what the associated cogs was of that and certainly wish you all the best in your, in your, in your next endeavors and it's been a pleasure working with you.

James Gruber (Chief Financial Officer)

Likewise. Thanks, Chase. So we have as far as the, the diluted margin profile on our X US increlix revenue it's about 2 to 1. So $2 of COGS to $1 of revenue and it was low single digit millions in Q1. We should have maybe a handful of similar orders. I think previously we have estimated annual ex US increlix revenue of 2 to 3 million. And that's still the estimate for 2026.

Chase Knickerbocker

Thank you.

OPERATOR

Thank you. This concludes the question and answer session. Thank you for your participation in today's conference. You may now disconnect.

Disclaimer: This transcript is provided for informational purposes only. While we strive for accuracy, there may be errors or omissions in this automated transcription. For official company statements and financial information, please refer to the company's SEC filings and official press releases. Corporate participants' and analysts' statements reflect their views as of the date of this call and are subject to change without notice.